LIVER CIRRHOSIS
Conditions
Keywords
LIVER CIRRHOSIS, MAGNESIUM, MINIMAL ENCEPHALOPATHY, MUSCLE WEAKNESS
Brief summary
Several studies have shown in patients magnesium deficiency with liver cirrhosis. Patients with liver cirrhosis showed considerably reduced muscle strength and muscle magnesium. We suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.
Detailed description
Magnesium is the fourth most abundant cation in the body and plays an important physiological role in many of its functions. There are no readily available and easy methods to assess magnesium status but it is estimated that magnesium deficiency is a common problem. Magnesium deficiency can cause a wide variety of features including hypocalcaemia, hypokalaemia and cardiac and neurological manifestations. Chronic low magnesium state has been associated with a number of chronic diseases including diabetes, hypertension, coronary heart disease, and osteoporosis. There are not enough studies on magnesium status in chronic cirrhotics who may be in depletion. However , several studies have shown in patients magnesium deficiency with liver cirrhosis. Patients with liver cirrhosis showed considerably reduced muscle strength and muscle Mg . Magnesium may have a role in the neuromuscular and neuropsychiatric manifestations of chronic liver disease (hepatic encephalopathy and muscle cramps). The use of magnesium as a therapeutic agent in asthma, myocardial infarction, and pre-eclampsia is also discussed. We suggest addition of magnesium to patients with established cirrhosis in order to reduce the neuromuscular and neuropsychiatric manifestations of chronic liver disease.
Interventions
DIETARY_SUPPLEMENTmagnesium
supply magnesium oxide for 6 weeks
DIETARY_SUPPLEMENTPlacebo
Sponsors
Meir Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* patients with liver cirrhosis
Exclusion criteria
* pregnant women * Patients with acute or chronic renal failure (cr\>1.5) * Congestive heart failure NYHA 3-4 * Patient with active cancer * Patients with dementia or mental retardation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in minimal hepatic encephalopathy | 6 weeks |
Secondary
| Measure | Time frame |
|---|---|
| change in muscle weakness | 6 weeks after intervention |
Other
| Measure | Time frame | Description |
|---|---|---|
| chang in other cirrhosis parameters | 6 weeks after intervention | change in liver function test (AST ALT GPT GGT ALBUMIN INR) change in magnesium level |
Countries
Israel
Contacts
Primary Contactkeren cohen, MD
Backup Contactyona kitay, MD
Outcome results
None listed